Seizures
RSSArticles
-
Intravenous Calcitonin Gene-Related Antibodies for the Prevention of Migraine
In a Phase 2 trial, antibodies to calcitonin gene-related peptide resulted in a significant decrease in migraine days measured from baseline to weeks 5 to 8 after one intravenous infusion of the medication, as compared to a placebo infusion. But the high-rate of placebo response (50%) warrants caution in the interpretation of the study results and requires more investigation. -
Cumulative Index: Volume 20, Numbers 1-12, Pages 1-96, September 2001 — August 2002
An index of Neurology Alert articles organized by topic. -
Increased Caloric Intake Increases the Risk of Alzheimer’s Disease
-
Neuropsychological Assessment Reduces False Positives in Mild Cognitive Impairment
Synopsis: Traditional comprehensive neuropsychological testing has greater reliability, sensitivity, and specificity than bedside screening tests in the accurate diagnosis of mild cognitive impairment. -
Role of Neurologists and Diagnostic Tests in the Management of DSP
Synopsis: Using the clinical history and simple, inexpensive laboratory tests, community-based outpatient neurologists were able to determine the cause of distal symmetric polyneuropathy in three-fourths of patients presenting with typical symptoms. -
Chemotherapy-Induced Neuropathy in Pediatrics
Synopsis: Chemotherapy-induced peripheral neuropathy is common in children treated for a variety of cancers, but the long-term prognosis for recovery is excellent. -
To Sleep, Perchance to Clear Our Beta-Amyloid
SYNOPSIS: Both animal studies and human data suggest that A-beta 42 amyloid is cleared from the brain during sleep, and that sleep deprivation may be a risk factor for the development of Alzheimer’s disease.
-
New Diagnostic Methods for Creutzfeldt-Jakob Disease
Synopsis: Novel noninvasive diagnostic tests for Creutzfeldt-Jakob disease (CJD; nasal brushings) and variant CJD (urinary prion proteins) are reported to be highly sensitive and specific in two recent studies.
-
Will New Approaches Help to Treat ALS?
-
Pharmacology Watch: High-Dose Rofecoxib Confirmed Prothrombotic, Study Shows
Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August suggesting an increase in cardiovascular events with rofecoxib (Vioxx). Now a large retrospect, the cohort study from the Tennessee Medicaid program seems to confirm the prothrombotic effects of rofecoxib, at least in high dose.